1.Amin, J, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. Journal of Hepatology 2006; 45: 197–203.
2.Amin, J, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938–945.
3.Duberg, A-S, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. Journal of Viral Hepatitis 2008; 15: 538–550.
4.Gidding, HF, et al. Hospital-related morbidity in people notified with hepatitis C; a population-based record linkage study in New South Wales, Australia. Journal of Hepatology 2010; 53: 43–49.
5.McDonald, SA, et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Statistical Methods in Medical Research 2009; 18: 271–283.
6.McDonald, SA, et al. A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland. British Journal of Cancer 2008; 99: 805–810.
7.Dore, GJ, et al. Is severe liver disease a common outcome for people with chronic hepatitis C? Journal of Gastroenterology and Hepatology 2002; 17: 423–430.
8.Poynard, T, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. Journal of Hepatology 2001; 34: 730–739.
9.Harris, HE, et al. Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. Epidemiology and Infection 2006; 134: 472–477.
10.Thomas, DL, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Journal of the American Medical Association 2000; 284: 450–456.
11.Kramer, JR, et al. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. American Journal of Gastroenterology 2005; 100: 56–63.
12.Fu, B, Tom, BD, Bird, SM. Re-weighted inference about hepatitis C virus-infected communities when analysing diagnosed patients referred to liver clinics. Statistical Methods in Medical Research 2009; 18: 303–320.
13.McDonald, SA, et al. Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991–2006. Epidemiology and Infection 2010 (in press).
14.McDonald, SA, et al. Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: A population-based record-linkage study. European Journal of Gastroenterology and Hepatology 2010; 22: 49–57.
15.CHeReL. The Centre for Health Record Linkage (www.cherel.org.au). Accessed 28 September 2009.
16.ChoiceMaker Technologies Inc. ChoiceMaker software. New York, USA.
17.Fabrizi, F, et al. Hepatitis C virus infection and the dialysis patient. Seminars in Dialysis 2007; 20: 416–422.
18.Kirkwood, BR, Sterne, JAC. Essential Medical Statistics, 2nd edn. Malden, Massachusetts: Blackwell Science Ltd, 2003.
19.Hennekens, CH, Buring, JE. Epidemiology in Medicine, 1st edn. Boston: Little Brown and Co., 1987.
20.Dolan, K, et al. Needle and syringe programs: a review of the evidence. Canberra: Australian Government Department of Health and Ageing, 2005.
21.Chu, C-J, Lee, S-D. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. Journal of Gastroenterology and Hepatology 2008; 23: 512–520.
22.Miller, ER, et al. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. Journal of Infection 2009; 58: 375–382.
23.National Centre in HIV Epidemiology and Clinical Research. Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs in Australia, 2009. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of NSW, 2009.
24.National Centre in HIV Epidemiology and Clinical Research. Australian NSP survey national data report, 2005–2009. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of NSW, 2010.
25.Gidding, HF, et al. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997–2006. Journal of Gastroenterology and Hepatology 2009; 24: 1648–1654.
26.Omland, LH, et al. The impact of HIV-1 co-infection on long-term mortality in patients with hepatitis C: a population-based cohort study. HIV Medicine 2009; 10: 65–71.
27.Uuskula, A, et al. High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs. Journal of Public Health 2008; 30: 119–125.
28.Mathers, BM, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 1733–1745.
29.Wiessing, L, Nardone, A. Ongoing HIV and viral hepatitis infections in IDUs across the EU, 2001–2005. Eurosurveillance 2006; 11: E061123.2.
30.CDC. Travelers' health, yellow book. Atlanta, GA: US Department of Health and Human Services, 2008.
31.Crofts, N, Aitken, CK, Kaldor, JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Medical Journal of Australia 1999; 170: 220–221.
32.Hagan, H, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. American Journal of Public Health 1995; 85: 1531–1537.
33.Hurley, SF, Jolley, DJ, Kaldor, JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997; 349: 1797–1800.
34.MacDonald, M, et al. Effectiveness of needle and syringe programmes for preventing HIV transmission. International Journal of Drug Policy 2003; 14: 353–357.
35.Kwon, JA, et al. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. Journal of Acquired Immune Deficiency Syndromes 2009; 51: 462–469.
36.Murray, JM, et al. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. International Journal of Epidemiology 2003; 32: 708–714.
37.Cherner, M, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005; 64: 1343–1347.
38.Benhamou, Y, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054–1058.
39.Goedert, JJ, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100: 1584–1589.
40.Sagnelli, E, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32: 1106–1110.
41.Thein, H-H, et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979–1991.
42.Zarski, JP, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. Journal of Hepatology 1998; 28: 27–33.
43.Donato, F, Boffetta, P, Puoti, M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. International Journal of Cancer 1998; 75: 347–354.
44.Puoti, M, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18: 2285–2293.
45.Benvegnu, L, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 2442–2448.
46.Ostapowicz, G, et al. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 1730–1735.
47.Thein, H-H, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418–431.
48.Danta, M, et al. Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection. Medical Journal of Australia 2002; 177: 240–245.
49.National Centre in HIV Epidemiology and Clinical Research. Australian NSP survey national data report, 2004–2008. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of NSW, 2008.
50.Micallef, JM, Kaldor, JM, Dore, GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Journal of Viral Hepatitis 2006; 13: 34–41.